COX.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 bal. 2023 @ 18:35):

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health...

Stats
Dzisiejszy wolumen	246 141
Średni wolumen	196 980
Kapitalizacja rynkowa	29.04M
EPS	€0 ( 2024-04-17 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.456
ATR14	€0.0560 (9.49%)

Wolumen Korelacja

Długi: -0.11 (neutral)

Krótki: -0.95 (very strong negative)

Signal:(45.399) Neutral

Nicox SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nicox SA Korelacja - Waluta/Towar

-0.68
( moderate negative )

-0.87
( strong negative )

0.00
( neutral )

-0.51
( weak negative )

0.18
( neutral )

0.67
( moderate )

Nicox SA Finanse

Annual	2022
Przychody:	€5.24M
Zysk brutto:	€3.27M (62.40 %)
EPS:	€0

FY	2022
Przychody:	€5.24M
Zysk brutto:	€3.27M (62.40 %)
EPS:	€0

FY	2021
Przychody:	€8.58M
Zysk brutto:	€7.23M (84.27 %)
EPS:	€-1.170

FY	2020
Przychody:	€14.42M
Zysk brutto:	€12.91M (89.49 %)
EPS:	€-0.540

Financial Reports:

No articles found.

Nicox SA

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.